{"title":"FDA approves first monotherapy standalone MDD treatment","authors":"Valerie A. Canady","doi":"10.1002/mhw.34313","DOIUrl":null,"url":null,"abstract":"<p>The Food and Drug Administration (FDA) last week approved the supplemental New Drug Application (sNDA) for spravato (esketamine), CII nasal spray considered the first and only monotherapy for adults with major depressive disorder (MDD) for adults who have failed to respond to at least two oral antidepressants.</p>","PeriodicalId":100916,"journal":{"name":"Mental Health Weekly","volume":"35 4","pages":"4-5"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mhw.34313","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The Food and Drug Administration (FDA) last week approved the supplemental New Drug Application (sNDA) for spravato (esketamine), CII nasal spray considered the first and only monotherapy for adults with major depressive disorder (MDD) for adults who have failed to respond to at least two oral antidepressants.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
